Companies formed

Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.

Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.

The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.


Oxford Medical Diagnostics develops and supplies breath analysis technologies for rapid, accurate, and low-cost monitoring of diseases and metabolic functions.

Incorporated in June 2004

Origin: Oxford University, Department of Physical and Theoretical Chemistry


Oxford Consultants for Social Inclusion (OCSI) helps local government identify deprived neighbourhoods, target resources, evaluate programme effectiveness and strengthen regeneration bids.

Incorporated in August 2003

Origin: Oxford University, Department of Social Policy and Intervention

A biotherapeutics company, established to exploit the work in Viral Hepatitis undertaken at Imperial College, London and at Oxford University through the Wellcome Trust Centre for Human Genetics.

Incorporated in July 2003

Origin: Oxford University, Wellcome Trust Centre for Human Genetics

ReOx is a drug discovery company that is building on the primary research of the founding academics to develop novel treatments for disease by controlling the activity of hypoxia inducible factor (HIF).

Incorporated in May 2003

Origin: Oxford University, Centre for Cellular and Molecular Physiology

Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.

Incorporated in February 2003

Origin: Oxford University, Department of Organic Chemistry


BioAnalab offers a contract testing service to the biopharmaceutical industry for the rapidly growing area of therapeutic monoclonal antibodies, with a longer-term strategy to develop diagnostics to measure levels of monoclonal antibodies and their immune response. In July 2009, BioAnaLab was acquired by Millipore Corp.

Incorporated in November 2002

Origin: Oxford University, Department of Pathology

Oxford Risk is the market-leading provider of customer risk profilers. Their products reveal the level of risk customers are willing and able to take with their financial investments.

Incorporated in November 2002

Origin: Oxford University, Nuffield Department of Population Health

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. In 2021, Oxford Immunotec was acquired by PerkinElmer.

Incorporated in October 2002

Origin: Oxford University, Nuffield Department of Clinical Medicine

Glycosolation technology.

Incorporated in August 2002

Origin: Oxford University, Organic Chemistry

Modification of proteins.

Incorporated in May 2002

Origin: Oxford University, Chemistry

Anti-cancer drugs.

Incorporated in January 2002

Origin: Oxford University, Chemistry


Specialised archaeological-based IT applications.

Incorporated in June 2001

Origin: Oxford University, Archaeology

Ready to get in touch?

Contact Us
© Oxford University Innovation